Current aspects of targeted therapy in head and neck tumors
暂无分享,去创建一个
Andreas Dietz | Gunnar Wichmann | Athanassios Giannis | A. Dietz | G. Wichmann | A. Boehm | C. Mozet | A. Giannis | Andreas Boehm | Christian Mozet
[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[2] H. Pospisil,et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression , 2007, Investigational New Drugs.
[3] Osamu Ohmori,et al. A novel low‐molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth , 2007, Molecular carcinogenesis.
[4] S Webb,et al. Intensity-modulated radiation therapy using a variable-aperture collimator. , 2003, Physics in medicine and biology.
[5] M. Kron,et al. Organ Preservation by Transoral Laser Microsurgery in Piriform Sinus Carcinoma , 2001, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[6] P. Harari,et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members , 2008, Oncogene.
[7] H. Pospisil,et al. Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells , 2008, Investigational New Drugs.
[8] J. Shah,et al. Neck dissection: then and now. , 2006, Auris, nasus, larynx.
[9] J. Armand,et al. Les inhibiteurs oraux de la voie du VEGF , 2007 .
[10] N. Curtin,et al. Pemetrexed disodium, a novel antifolate with multiple targets. , 2001, The Lancet. Oncology.
[11] D. Wong,et al. Dissecting the Akt/Mammalian Target of Rapamycin Signaling Network: Emerging Results from the Head and Neck Cancer Tissue Array Initiative , 2007, Clinical Cancer Research.
[12] J. Grandis,et al. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer , 2008, Head & neck.
[13] D. Brasnu,et al. The Laryngologist in Organ Preservation for Laryngeal Cancer , 2008, The Laryngoscope.
[14] A. Dietz,et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.
[15] S. Bentzen,et al. The need for adverse effects reporting standards in oncology clinical trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Mimeault,et al. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers , 2007, Journal of cellular and molecular medicine.
[17] G. Bepler,et al. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Heron,et al. Phase II trial of docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (RT), P, and E in locally advanced head and neck squamous cell carcinoma (HNSCC) , 2007 .
[19] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[20] L. Siu,et al. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck , 2008, Current opinion in oncology.
[21] C. Arteaga,et al. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. , 2003, Seminars in oncology.
[22] Mark R. Green,et al. Targeting targeted therapy. , 2004, The New England journal of medicine.
[23] C. J. Barnes,et al. Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer , 2007, Clinical Cancer Research.
[24] C. Snyderman,et al. Endoscopic techniques for pathology of the anterior cranial fossa and ventral skull base. , 2006, Journal of the American College of Surgeons.
[25] S. Franco,et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. , 2008, Annals of Oncology.
[26] A. Harris,et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Lahn,et al. Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in vitro soft-agar cloning experiments , 2007, Investigational New Drugs.
[28] M. Leblanc,et al. Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R H Wheeler,et al. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Grandis,et al. Head and neck cancer: recent advances and new standards of care. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Rodrigo,et al. Relación entre la expresión de FAK y p53 en los carcinomas epidermoides de laringe , 2007 .
[32] A. Schueler,et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] W Korb,et al. [Clinical efficiency and the influence of human factors on ear, nose, and throat navigation systems]. , 2006, HNO.
[34] K. Fu,et al. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Saif,et al. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic , 2007, Anti-cancer drugs.
[36] R. Puri,et al. Tumor regression mechanisms by IL‐13 receptor–targeted cancer therapy involve apoptotic pathways , 2003, International journal of cancer.
[37] Quentin Liu,et al. Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase , 2007, International journal of cancer.
[38] L. Tuason,et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results , 1997, Head & neck.
[39] J. Bourhis,et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Ralph Mazitschek,et al. Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases. , 2004, Current opinion in chemical biology.
[41] M. Lacouture. Mechanisms of cutaneous toxicities to EGFR inhibitors , 2006, Nature Reviews Cancer.
[42] R. Day,et al. Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .
[43] P. Coates,et al. ΔNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck , 2007, The Journal of pathology.
[44] J. Mendelsohn. Targeting the epidermal growth factor receptor for cancer therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] R. Tishler,et al. Phase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early results , 2007 .
[46] I. Weissman,et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.
[47] Jessica Wang-Rodriguez,et al. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. , 2007, Archives of otolaryngology--head & neck surgery.
[48] J. Rodrigo,et al. [Relationship between FAK and P53 expression in squamous cell carcinomas of the larynx]. , 2007, Acta otorrinolaringologica espanola.
[49] B. Homey,et al. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. , 2007, The New England journal of medicine.
[50] C. Trantakis,et al. Ist der Vorteil eines Navigationssystems in der HNO-Chirurgie messbar? , 2006, HNO.
[51] Suzanne L Wolden,et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] B. Melichar,et al. Successful management of infusion reaction accompanying the start of cetuximab therapy , 2007, Supportive Care in Cancer.
[53] E. Raymond,et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck , 2001, British Journal of Cancer.
[54] J. Shah,et al. Cyclooxygenase‐2: A novel molecular target for the prevention and treatment of head and neck cancer , 2002, Head & neck.